Company intelligence / Profile preview
Helicore Biopharma
South San Francisco, California, United Stateshelicore.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Helicore’s lead program, HCR‑188, is a first-in-class monoclonal antibody that binds circulating GIP ligand. The first participant was dosed in a Phase 1 single and multiple ascending dose study in March 2025. Top-line safety data are expected in the second half of 2025. Preclinical studies suggest preferential loss of fat over lean mass when combined with GLP‑1 therapies, potentially offering improved efficacy and tolerability compared to current obesity treatments. No clinical efficacy results have been reported yet.
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Monoclonal antibodies (mAbs)Antibody conjugates (including GLP-1 combinations)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Ridgeline Therapeutics – protein engineering/discovery support via Versant Ventures’ discovery engine in Switzerland.No major pharma partnerships disclosed as of May 2025.
Beyond the preview
Go deeper on Helicore Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helicore Biopharma.